Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and BMS-986016 with Microdialysis in Recurrent Glioblastoma
NCT03493932Phase 1Completed
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Sep 2018
- Primary completion
- Apr 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of relatlimab in glioblastoma (GBM), sponsored by National Institute of Neurological Disorders and Stroke. Primary endpoints: Increase of Interferon Gamma Levels at Day 8, Microdialysis Catheter Safety at Day 8 and 1 more. Started Sep 2018; status: completed.
02
Drugs
relatlimab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03493932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03493932.